Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab cardiovascular outcomes trial in high-risk patients without prior myocardial infarction or stroke
2023-503673-38-00Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Evolocumab with Placebo (2 arms). Primary endpoints: Time to CHD death, MI, or ischemic stroke and Time to CHD death, MI, ischemic stroke, or ischemia-driven arterial revascularization. Started Apr 2024; status: completed.
02
Drugs
evolocumab
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on 2023-503673-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503673-38-00.